Group 1 - JiTai Technology has completed a Series D financing round, raising a total of 400 million RMB, led by the Beijing Medical Health Industry Investment Fund and the Daxing District Industrial Investment Fund [1] - The funds will be used to advance multiple strategic priorities, including platform automation upgrades, self-developed product pipeline advancement, deepening international strategic cooperation, and attracting high-end talent [1] - The cell and gene therapy (CGT) sector is identified as a key area for drug innovation, following small molecule drugs and antibody drugs [1] Group 2 - In 2024, Beijing's Science and Technology Commission and other departments will release a three-year action plan to accelerate innovation in the CGT industry, aiming to cultivate over 20 leading CGT technology companies by 2027 [1] - JiTai Technology has established the Open CGT technology platform, focusing on addressing industry pain points in precise drug delivery, reducing development barriers and costs, and facilitating the research and clinical transformation of breakthrough CGT therapies [1] - The Open CGT platform aims to connect research capabilities from top universities, resources from major hospitals, and the full R&D chain of CGT innovative pharmaceutical companies, with its first project already launched [1]